tweenvest

TenNor Therapeutics (Suzhou) Limited (SEHK: 6872)

Health Care · Biotechnology · CN

HK$68.60

-1.44% today · -67.5% 1Y

Public summary
A free snapshot of TenNor Therapeutics (Suzhou) Limited, with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

TenNor Therapeutics (Suzhou) Limited (SEHK: 6872) operates in the Biotechnology industry within the Health Care sector. The company is valued at $457.56M and employs 56 people.

Over the last twelve months the share price has lost 67.5%, trading between 65.20 and 287.00.

Tweenvest scores TenNor Therapeutics (Suzhou) Limited across four factors: quality 44/100, value 100/100. Its strongest factor is value.

6872 price history

May 22, 2026 · 211.00Weekly closes 66.00 – 264.80Nov 16, 2026 · 68.60

Key figures

Market cap
$457.56M
Revenue (TTM)
—
P/E
-16.89
EPS
-4.28
Dividend yield
—
Beta (5Y)
—
52-week high
HK$287.00
52-week low
HK$65.20
Avg volume (3M)
—
Shares outstanding
52.33M
Employees
56
Next earnings
—

About TenNor Therapeutics (Suzhou) Limited

TenNor Therapeutics (Suzhou) Limited specializes in researching, developing, and bringing to market unique therapies for illnesses arising from bacterial infections and bacterial metabolic functions. Its robust product pipeline includes Rifasutenizole (TNP-2198), designed to combat Helicobacter pylori infections. Another key asset, Rifaquizinone (TNP-2092), is being advanced in an injectable formulation to treat Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and infections associated with Left Ventricular Assist Devices (LVADs). An oral variant of TNP-2092 is aimed at addressing conditions linked to gut bacterial metabolism, such as Hepatic Encephalopathy (HE) and Irritable Bowel Syndrome with Diarrhea (IBS-D). Furthermore, their development programs feature a topical TNP-2092 for confronting drug-resistant bacterial strains and biofilm-mediated infections; TNBi-1, a novel narrow-spectrum small molecule for H. pylori; TNBi-2, a broad-spectrum, multi-targeting small molecule for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD); and TNBm-1, a broad-spectrum bifunctional small molecule for metabolic disorders. The company was established in 2012 and maintains its headquarters in Suzhou, China.

ISIN
CNE100007KG6
Founded
2012
Listed since
May 22, 2026
Exchange
The Stock Exchange of Hong Kong Ltd.
Currency
HKD
CompanyMarket capPriceDay
MiMedx Group, Inc.NasdaqCM: MDXG$464.04M$3.180.00%
Thalys Medical Technology Group CorporationSHSE: 603716$462.69MCN¥13.91-2.59%
Assembly Biosciences, Inc.NasdaqGS: ASMB$460.74M$22.50+5.68%
HanchorBio Inc.TWSE: 7827$458.12MNT$108.00-9.62%
Wuhan Hiteck Biological Pharma Co.,LtdSZSE: 300683$456.90MCN¥23.30+3.42%
Ever Supreme Bio Technology Co., LtdTPEX: 6712$452.94MNT$148.00+1.72%
Qurient Co., Ltd.KOSDAQ: A115180$441.89M₩14,510.00-11.74%
Qingdao Vland Biotech INC.SHSE: 603739$440.25MCN¥11.60+0.87%

Browse every Biotechnology company →